2nd World Congress on
CONTROVERSIES IN HEMATOLOGY

BARCELONA, SPAIN • SEPTEMBER 6-8, 2012

2ND ANNOUNCEMENT
& CALL FOR ABSTRACTS

ABSTRACT SUBMISSION DEADLINE: JUNE 27, 2012

cohem@comtecmed.com • www.comtecmed.com/cohem
Dear Friends and Colleagues,

Following the great success of the 1st World Congress on Controversies in Hematology (COHEM) which attracted almost 500 participants from more than 60 countries, we are delighted to invite you to participate in the 2nd World Congress on Controversies in Hematology (COHEM) which will take place on September 6-8, 2012.

The 2nd COHEM Congress aims to circulate up to date information and to provide a unique opportunity for world leaders in the field to debate the most vital and contentious issues in benign and malignant Hematology. This thought-provoking academic dialogue will raise the most challenging current clinical and technological questions.

By allocating substantial time for discussions following each debate, audience members are encouraged to take a participating role in this influential academic dialogue. These exciting debates will highlight the key issues raised in 2011 and 2012 and provide clinicians with state-of-the-art recommendations regarding patient care.

We invite you to participate in the 2nd COHEM Congress and to take an active role in this innovative and interactive experience.

We look forward to welcoming you at this fascinating scientific event!

Prof. Robin Foà  
Italy

Prof. Rüdiger Hehlmann  
Germany

Prof. Eliezer Rachmilewitz  
Israel

Prof. Giuseppe Saglio  
Italy

Co-Chairpersons

Prof. Emili Montserrat  
Spain

Prof. Charles Schiffer  
USA

FACULTY

(Preliminary List)

E. Angelucci, Italy  
M. Baccarani, Italy  
T. Barbui, Italy  
B. Barlogie, USA  
M. Boccadoro, Italy  
A.K. Burnett, UK  
J. Bussell, USA  
Y. Cabantchik, Israel  
M.D. Cappellini, Italy  
B. Coiffier, France  
J. Connors, Canada  
V. Diehl, Germany  
A. Engert, Germany  
J. Esteve, Spain  
A. Falanga, Italy  
B. Falini, Italy  
P. Fenaux, France  
R. Foà, Italy  
G. Gaidano, Italy  
A. Hagenbeek, The Netherlands  
C. Haioun, France  
R. Hehlmann, Germany  
D. Hoelzer, Germany  
E. Kimby, Sweden  
N. Kröger, Germany  
F. Lo-Coco, Italy  
J.P. Marie, France  
E. Montserrat, Spain  
A. Nagler, Israel  
E. Olavarria, Spain  
A. Palumbo, Italy  
A. Piga, Italy  
E. Rachmilewitz, Israel  
A.C. Rawstron, UK  
J.M. Ribera, Spain  
G. Rodgers, USA  
G. Saglio, Italy  
M.M. Samama, France  
J.F. San-Miguel, Spain  
V. Santini, Italy  
M.A. Sanz, Spain  
C. Schiffer, USA  
S. Sheth, USA  
J. Sierra, Spain  
R. Stasi, UK  
J.L. Steegmann, Spain  
S. Stilgenbauer, Germany  
A. Tefferi, USA  
W. Vainchenker, France  
J.L. Vives Corrons, Spain  
U. Vitolo, Italy  
J. Yahalom, USA  
P.L. Zinzani, Italy
### THURSDAY, SEPTEMBER 6, 2012

**HALL A**

**15:30-17:45**  
**PLENARY SESSION 1**  
DEBATES IN APL, AML & CLL

Chairpersons opening remarks

Is there a possibility to cure APL without chemotherapy in the future?  
Moderator: **G. Saglio**, Italy  
Yes: **M.A. Sanz**, Spain  
No: **F. Lo-Coco**, Italy

Has molecular characterization of cytogenetically normal AML been a major advance in the management of patients?  
Moderator: **A.K. Burnett**, UK  
Yes: **B. Falini**, Italy  
No: **C. Schiffer**, USA

---

### FRIDAY, SEPTEMBER 7, 2012

**HALL A**

**08:30-10:00**  
**SESSION 2**  
AML

Should patients with high risk MDS (and AML in early relapse) proceed directly to allogeneic transplantation without prior induction chemotherapy?  
Moderator: **M.A. Sanz**, Spain  
Yes: **A.K. Burnett**, UK  
No: **P. Fenaux**, France

Should older patients with AML be considered for lower intensity approaches rather than 3 & 7?  
Moderator: **J. Esteve**, Barcelona  
Yes: **J. Sierra**, Spain  
No: **C. Schiffer**, USA

**10:00-10:30**  
**Coffee Break**

**10:30-12:00**  
**SESSION 4**  
ALL

Should ‘pediatric’-like strategies be extended over the age of 35?  
Moderator: **D. Hoelzer**, Germany  
Yes: **J.M. Ribera**, Spain  
No: **J.P. Marie**, France

Can ALL be managed without chemotherapy/transplant?  
Moderator: **C. Schiffer**, USA  
Yes: **R. Foà**, Italy  
No: **D. Hoelzer**, Germany

**12:00-13:00**  
**Lunch Break**

**13:00-14:15**  
TBA

---

**HALL A**

**14:15-15:45**  
**SESSION 6**  
MDS

Is iron chelation of importance in the management of myelodysplasia?  
Moderator: **G. Saglio**, Italy  
Yes: **E. Rachmilewitz**, Israel  
No: **A. Tefferi**, USA

After failure of hypomethylating agent-based therapy in myelodysplastic syndromes: which is the best strategy?  
Moderator: **C. Schiffer**, USA  
BMT: **N. Kröger**, Germany  
Investigational drugs: **V. Santini**, Italy

**15:45-16:15**  
**Coffee Break**

**16:15-17:45**  
**SESSION 8**  
MPNs

Is the development of JAK 2 inhibitors an important advance in the treatment of MPNs?  
Moderator: **T. Barbui**, Italy  
Yes: **TBA**  
No: **A. Tefferi**, USA

Is the recommended hematocrit target in polycythemia vera evidence-based?  
Moderator: **R. Hehlmann**, Germany  
Yes: **TBA**  
No: **T. Barbui**, Italy
PRELIMINARY SCIENTIFIC PROGRAM

FRIDAY, SEPTEMBER 7, 2012

HALL B

08:30-10:00  SESSION 3
Monoclonal B-cell lymphocytosis: Much ado about nothing?
Moderator: R. Foà, Italy
Yes: E. Montserrat, Italy
No: A.C. Rawstron, UK

Is the whole better than the sum of its parts? All ‘fit’ older patients should receive FCR
Moderator: E. Montserrat, Spain
Yes: S. Stilgenbauer, Germany
No: R. Foà, Italy

10:00-10:30  Coffee Break

10:30-12:00  SESSION 5
Should all patients with follicular leukemia receive maintenance therapy?
Moderator: A. Hagenbeek, The Netherlands
Yes: E. Kimby, Sweden
No: N. Kröger, Germany

Is there a role of HDT-ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era?
Moderator: N. Kröger, Germany
Yes: B. Coiffier, France
No: A. Hagenbeek, The Netherlands

12:00-13:00  Lunch Break

HALL B

14:15-15:45  SESSION 7
HODGKIN’S DISEASE
Do we have one or two shots for cure in advanced Hodgkin’s disease? Kairos or Chronos?
Moderator: TBA
Pro Chronos: late intensification: J. Connors, Canada
Pro Kairos: early intensification: TBA

Should therapy for HD be modified by the results of the early PET?
Moderator: TBA
Yes: P.L. Zinzani, Italy
No: A. Engert, Germany

15:45-16:15  Coffee Break

16:15-17:45  SESSION 9
Should all patients with follicular leukemia receive maintenance therapy?
Moderator: A. Hagenbeek, The Netherlands
Yes: E. Kimby, Sweden
No: N. Kröger, Germany

Is there a role for HDT-ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era?
Moderator: N. Kröger, Germany
Yes: B. Coiffier, France
No: A. Hagenbeek, The Netherlands

12:00-13:00  Lunch Break

SATURDAY, SEPTEMBER 8, 2012

HALL A

08:30-10:00  SESSION 10
CML
Are TKI sufficient for the treatment of CML, or should TKI be combined with other agents or treatment modalities?
Moderator: G. Saglio, Italy
Yes: R. Hehlmann, Germany
No: M. Baccarani, Italy

Should patients treated with second line TKIs be considered for allo BMT?
Moderator: R. Hehlmann, Germany
Yes: E. Olavarria, Spain
No: J.L. Steegmann, Spain

10:00-10:30  Coffee Break

HALL A

10:30-12:00  SESSION 12
HEMOGLOBINOPATHIES
Is it justified to perform BMT in hemoglobinopathies using unrelated and/or partially mismatched donors?
Moderator: E. Rachmilewitz, Israel
Yes: E. Angelucci, Italy
No: M.D. Cappellini, Italy

Is there a rationale for treatment of sickle cell anemia except for acute complications?
Moderator: G. Rodgers, USA
Yes: S. Sheth, USA
No: J.L. Vives Corrons, Spain

12:00-13:00  Lunch Break
## Hall A

### 13:00-14:15 TBA

### 14:15-15:15 **SESSION 14**

**BIOMARKERS**

Are the new molecular and cytogenetic markers useful for the management of MNP?

**Moderator:** A. Tefferi, USA

**Yes:** W. Vainchenker, France  
**No:** TBA

Is serum ferritin a sufficient marker for evaluation and monitoring treatment of iron overload?

**Moderator:** E. Rachmilewitz, Israel  
**Yes:** A. Piga, Italy  
**No:** Y. Cabantchik, Israel

### 15:45-16:15 **Coffee Break**

### 16:15-17:30 **PLENARY SESSION 16**

**DEBATES IN MM & CML**

**MM - Cure versus control:** Which is the best strategy?

**Moderator:** J.F. San-Miguel, Spain  
**Cure:** B. Barlogie, USA  
**Control:** M. Boccadoro, Italy

Preferred 1st line treatment of CML: 2nd generation TKI or optimized imatinib?

**Moderator:** J.L. Steegmann, Spain  
**2nd generation TKI:** G. Saglio, Italy  
**Optimized imatinib:** R. Hehlmann, Germany

### Hall B

### 08:30-10:00 **SESSION 11**

**MULTIPLE MYELOMA**

Transplant in MM patients: Early versus late

**Moderator:** J.F. San-Miguel, Spain  
**Early:** A. Nagler, Israel  
**Late:** M. Boccadoro, Italy

Is there a role for maintenance therapy?

**Moderator:** M. Boccadoro, Italy  
**Yes:** A. Palumbo, Italy  
**No:** J.F. San-Miguel, Spain

### 10:00-10:30 **Coffee Break**

### 10:30-12:00 **SESSION 13**

**INFECTIONS**

Should anti-infection prophylaxis be given before / after BMT?

**Moderator:** A. Nagler, Israel  
**Yes:** TBA  
**No:** E. Olavarria, Spain

Are all the GFs the same?

**Moderator:** TBA  
**Yes:** G. Gaidano, Italy  
**No:** TBA

### 12:00-13:00 **Lunch Break**

### 14:15-15:45 **SESSION 15**

**COAGULATION**

What should be the next step after failure of steroids in ITP – splenectomy versus Rituximab or TPO mimetics?

**Moderator:** M.M. Samama, France  
**Splenectomy & Rituximab:** R. Stasi, UK  
**TPO mimetics:** J. Bussell, USA

New anticoagulants: Monitoring or not Monitoring?

**Moderator:** J. Bussell, USA  
**Monitoring:** M.M. Samama, France  
**Not Monitoring:** A. Falanga, Italy
2nd World Congress on
CONTROVERSIES IN HEMATOLOGY
BARCELONA, SPAIN • SEPTEMBER 6-8, 2012
cohem@comtecmed.com
www.comtecmed.com/cohem

GENERAL INFORMATION

VENUE
Princesa Sofia Hotel
Plaza Pius XII, 4
Barcelona 08028, Spain
Website: www.princesasofia.com

REGISTRATION FEES

<table>
<thead>
<tr>
<th></th>
<th>Early Registration until June 27, 2012</th>
<th>Late Registration from June 28 until August 27, 2012</th>
<th>From August 28, 2012 and on-site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants -</td>
<td>€540</td>
<td>€590</td>
<td>€650</td>
</tr>
<tr>
<td>Physicians and Scientists</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Residents, Nurses, Students</td>
<td>€385</td>
<td>€430</td>
<td>€470</td>
</tr>
</tbody>
</table>

Registration fees include: Participation in scientific sessions, Congress bag, program and abstract book, all printed material of the Congress, invitation to the Welcome Reception, coffee breaks, lunch on Friday and Saturday.

ACCOMMODATION
ComtecMed is the official travel agent for the 2nd World Congress on Controversies in Hematology (COHEM) and is offering special reduced rates for the Congress participants.

CONGRESS SECRETARIAT
Please do not hesitate to contact the Secretariat if you require any additional information or assistance. Please address all correspondence to: cohem@comtecmed.com

LIABILITY AND INSURANCE
The Congress Secretariat and Organizers cannot accept liability for personal accidents, nor loss of or damage to private property of participants, either during or directly arising from the 2nd World Congress on Controversies in Hematology (COHEM). Participants should make their own arrangements with respect to health and travel insurance.